Immune checkpoint inhibitors (e.g., PD-1/PD-L1 and CTLA-4 inhibitors) and targeted therapies (e.g., EGFR inhibitors, ALK inhibitors) have become an integrated part of NSCLC treatment (6). Here, EGFR is linked to non-small cell lung carcinoma.